S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.40 (+0.11%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   353.15 (+2.08%)
GOOGL   2,845.99 (+0.77%)
TSLA   774.39 (+2.75%)
AMZN   3,425.26 (+0.27%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.02 (-0.03%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.40 (+0.11%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   353.15 (+2.08%)
GOOGL   2,845.99 (+0.77%)
TSLA   774.39 (+2.75%)
AMZN   3,425.26 (+0.27%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.02 (-0.03%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.40 (+0.11%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   353.15 (+2.08%)
GOOGL   2,845.99 (+0.77%)
TSLA   774.39 (+2.75%)
AMZN   3,425.26 (+0.27%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.02 (-0.03%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.40 (+0.11%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   353.15 (+2.08%)
GOOGL   2,845.99 (+0.77%)
TSLA   774.39 (+2.75%)
AMZN   3,425.26 (+0.27%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.02 (-0.03%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
NYSE:JNJ

Johnson & Johnson Stock Forecast, Price & News

$164.36
-0.50 (-0.30 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$163.89
$165.65
50-Day Range
$163.81
$179.47
52-Week Range
$133.65
$179.92
Volume4.40 million shs
Average Volume7.09 million shs
Market Capitalization$432.67 billion
P/E Ratio24.72
Dividend Yield2.57%
Beta0.71
30 days | 90 days | 365 days | Advanced Chart
Receive JNJ News and Ratings via Email

Sign-up to receive the latest news and ratings for Johnson & Johnson and its competitors with MarketBeat's FREE daily newsletter.


Johnson & Johnson logo

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.77 out of 5 stars

Medical Sector

30th out of 1,351 stocks

Pharmaceutical Preparations Industry

13th out of 664 stocks

Analyst Opinion: 2.4Community Rank: 4.4Dividend Strength: 4.2Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Johnson & Johnson (NYSE:JNJ) Frequently Asked Questions

Is Johnson & Johnson a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Johnson & Johnson stock.
View analyst ratings for Johnson & Johnson
or view top-rated stocks.

What stocks does MarketBeat like better than Johnson & Johnson?

Wall Street analysts have given Johnson & Johnson a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Johnson & Johnson wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Johnson & Johnson's next earnings date?

Johnson & Johnson is scheduled to release its next quarterly earnings announcement on Tuesday, October 19th 2021.
View our earnings forecast for Johnson & Johnson
.

How can I listen to Johnson & Johnson's earnings call?

Johnson & Johnson will be holding an earnings conference call on Tuesday, October 19th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) posted its quarterly earnings data on Tuesday, July, 20th. The company reported $2.48 EPS for the quarter, topping the consensus estimate of $2.29 by $0.19. The business earned $23.31 billion during the quarter, compared to the consensus estimate of $22.54 billion. Johnson & Johnson had a net margin of 19.92% and a trailing twelve-month return on equity of 37.06%. The firm's quarterly revenue was up 27.1% compared to the same quarter last year. During the same period in the prior year, the company earned $1.67 EPS.
View Johnson & Johnson's earnings history
.

How has Johnson & Johnson's stock price been impacted by Coronavirus (COVID-19)?

Johnson & Johnson's stock was trading at $131.80 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, JNJ shares have increased by 24.7% and is now trading at $164.36.
View which stocks have been most impacted by COVID-19
.

How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?

Johnson & Johnson announced a quarterly dividend on Monday, July 19th. Investors of record on Tuesday, August 24th will be paid a dividend of $1.06 per share on Tuesday, September 7th. This represents a $4.24 dividend on an annualized basis and a dividend yield of 2.58%. The ex-dividend date of this dividend is Monday, August 23rd.
View Johnson & Johnson's dividend history
.

Is Johnson & Johnson a good dividend stock?

Johnson & Johnson pays an annual dividend of $4.24 per share and currently has a dividend yield of 2.57%. Johnson & Johnson has been increasing its dividend for 59 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Johnson & Johnson is 52.80%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Johnson & Johnson will have a dividend payout ratio of 41.17% next year. This indicates that Johnson & Johnson will be able to sustain or increase its dividend.
View Johnson & Johnson's dividend history.

What guidance has Johnson & Johnson issued on next quarter's earnings?

Johnson & Johnson issued an update on its FY 2021 earnings guidance on Wednesday, August, 4th. The company provided earnings per share guidance of $9.600-$9.700 for the period, compared to the Thomson Reuters consensus estimate of $9.520. The company issued revenue guidance of $93.80 billion-$94.60 billion, compared to the consensus revenue estimate of $91.30 billion.

What price target have analysts set for JNJ?

8 brokers have issued 1-year target prices for Johnson & Johnson's shares. Their forecasts range from $175.00 to $200.00. On average, they anticipate Johnson & Johnson's stock price to reach $190.38 in the next twelve months. This suggests a possible upside of 15.8% from the stock's current price.
View analysts' price targets for Johnson & Johnson
or view top-rated stocks among Wall Street analysts.

Who are Johnson & Johnson's key executives?

Johnson & Johnson's management team includes the following people:
  • Alex Gorsky, Chairman & Chief Executive Officer
  • Joseph J. Wolk, Chief Financial Officer & Executive Vice President
  • Paulus Stoffels, Chief Scientific Officer
  • James D. Swanson, Global Chief Information Officer & Executive VP
  • Michael H. Ullmann, Executive Vice President & General Counsel

What is Alex Gorsky's approval rating as Johnson & Johnson's CEO?

2,535 employees have rated Johnson & Johnson CEO Alex Gorsky on Glassdoor.com. Alex Gorsky has an approval rating of 94% among Johnson & Johnson's employees. This puts Alex Gorsky in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Johnson & Johnson own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Johnson & Johnson investors own include AT&T (T), Pfizer (PFE), Verizon Communications (VZ), The Walt Disney (DIS), NVIDIA (NVDA), Intel (INTC), JPMorgan Chase & Co. (JPM), Cisco Systems (CSCO), The Procter & Gamble (PG) and AbbVie (ABBV).

What is Johnson & Johnson's stock symbol?

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

Who are Johnson & Johnson's major shareholders?

Johnson & Johnson's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.79%), BlackRock Inc. (7.27%), State Street Corp (5.40%), Geode Capital Management LLC (1.60%), Bank of New York Mellon Corp (1.25%) and Northern Trust Corp (1.19%). Company insiders that own Johnson & Johnson stock include Ashley Mcevoy, Hubert Joly, Kathryn E Wengel, Michael E Sneed and William D Perez.
View institutional ownership trends for Johnson & Johnson
.

Which institutional investors are selling Johnson & Johnson stock?

JNJ stock was sold by a variety of institutional investors in the last quarter, including Sanders Capital LLC, Vontobel Asset Management Inc., CIBC Private Wealth Group LLC, AQR Capital Management LLC, abrdn plc, State of Wisconsin Investment Board, SG Americas Securities LLC, and Northern Trust Corp.
View insider buying and selling activity for Johnson & Johnson
or view top insider-selling stocks.

Which institutional investors are buying Johnson & Johnson stock?

JNJ stock was purchased by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Amundi, Franklin Resources Inc., State Street Corp, Renaissance Technologies LLC, Vanguard Group Inc., BlackRock Inc., and Royal Bank of Canada. Company insiders that have bought Johnson & Johnson stock in the last two years include Hubert Joly, and William D Perez.
View insider buying and selling activity for Johnson & Johnson
or or view top insider-buying stocks.

How do I buy shares of Johnson & Johnson?

Shares of JNJ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Johnson & Johnson's stock price today?

One share of JNJ stock can currently be purchased for approximately $164.36.

How much money does Johnson & Johnson make?

Johnson & Johnson has a market capitalization of $432.67 billion and generates $82.58 billion in revenue each year. The company earns $14.71 billion in net income (profit) each year or $8.03 on an earnings per share basis.

How many employees does Johnson & Johnson have?

Johnson & Johnson employs 134,500 workers across the globe.

Does Johnson & Johnson have any subsidiaries?

The following companies are subsidiares of Johnson & Johnson: ALZA Corporation, Abott Medical Optics, Acclarent, Actelion Pharmaceuticals, Advanced Sterilization Products Services Inc., Alios BioPharma, Animas Corporation, Apsis, Apsis Germany GmbH, Aragon Pharmaceuticals, Auris Health, Beijing Dabao Cosmetics Co., Berna Rhein B.V., BioMedical Enterprises, Biosense Webster, Biosense Webster (Israel) Ltd., CNA Development GmbH, Centocor Research & Development, Ci:z Holdings, Cilag AG, Cilag GmbH International, Cilag Holding AG, Cilag Holding Finance Unlimited Company, Cilag Pharmaceuticals GmbH, Codman & Shurtleff, Coherex Medical, Conor MedSystems, Cordis Financing Corporation, Cordis LLC, Cordis de Mexico, Covagen AG, Crucell N.V., DePuy France, DePuy International Limited, DePuy Ireland Unlimited Company, DePuy Mitek, DePuy Orthopaedics, DePuy Products, DePuy Spine, DePuy Synthes, DePuy Synthes Apollo Limited, DePuy Synthes Eos Limited, DePuy Synthes Gorgan Limited, DePuy Synthes Jason Limited, DePuy Synthes Leto S.A.R.L., DePuy Synthes Products, DePuy Synthes Sales, Diabetes Diagnostics, EES, Ethicon, Ethicon Endo-Surgery, Ethicon Endo-Surgery LLC, Ethicon Holding Sarl, Ethicon Ireland, Ethicon LLC, Ethicon PR Holdings, Ethicon US, Ethicon Women's Health & Urology Sarl, Ethnor del Istmo, FMS Future Medical System SA, GMED Healthcare BVBA, Global Investment Participation B.V., J&J Holdings (Nevada), J-C Health Care Ltd., J.C. General Services CVBA, JJC Acquisition Company B.V., JJHC, JNJ International Investment LLC, JOM Pharmaceutical Services, Janssen, Janssen Biologics (Ireland), Janssen Biologics B.V., Janssen Biotech, Janssen Cilag Farmaceutica S.A., Janssen Egypt, Janssen Global Services, Janssen Infectious Diseases-Diagnostics BVBA, Janssen Irish Finance Company UC, Janssen Korea Ltd., Janssen Oncology, Janssen Ortho LLC, Janssen Pharmaceutica NV, Janssen Pharmaceutical, Janssen Pharmaceutical K.K., Janssen Pharmaceutical Sciences Unlimited Company, Janssen Pharmaceuticals, Janssen Products, Janssen R&D Ireland, Janssen Research & Development, Janssen Sciences Ireland UC, Janssen Scientific Affairs, Janssen Supply Group, Janssen Vaccines & Prevention B.V., Janssen Vaccines AG, Janssen Vaccines Corp., Janssen de Mexico, Janssen-Cilag, Janssen-Cilag A/S, Janssen-Cilag AB, Janssen-Cilag AG, Janssen-Cilag AS, Janssen-Cilag B.V., Janssen-Cilag Farmaceutica, Janssen-Cilag Farmaceutica Ltda., Janssen-Cilag GmbH, Janssen-Cilag Kft., Janssen-Cilag Limited, Janssen-Cilag Limited (UK), Janssen-Cilag Manufacturing, Janssen-Cilag NV, Janssen-Cilag OY, Janssen-Cilag Pharma GmbH, Janssen-Cilag Pharmaceutical S.A.C.I., Janssen-Cilag Pty Ltd, Janssen-Cilag S.A., Janssen-Cilag S.A., Janssen-Cilag S.A. de C.V., Janssen-Cilag S.p.A., Janssen-Cilag de Mexico, Johnson & Johnson (China) Investment Ltd., Johnson & Johnson (China) Ltd., Johnson & Johnson (Hong Kong) Limited, Johnson & Johnson (Ireland) Limited, Johnson & Johnson (Middle East) Inc., Johnson & Johnson (New Zealand) Limited, Johnson & Johnson (Philippines), Johnson & Johnson (Proprietary) Limited, Johnson & Johnson (Thailand) Ltd., Johnson & Johnson AB, Johnson & Johnson AG, Johnson & Johnson Belgium Finance Company, Johnson & Johnson Consumer (Hong Kong) Limited, Johnson & Johnson Consumer (Thailand) Limited, Johnson & Johnson Consumer Holdings France, Johnson & Johnson Consumer Inc., Johnson & Johnson Consumer Services EAME Ltd., Johnson & Johnson European Treasury Company, Johnson & Johnson Finance Corporation, Johnson & Johnson Finance Limited, Johnson & Johnson Financial Services GmbH, Johnson & Johnson Gesellschaft m.b.H., Johnson & Johnson GmbH, Johnson & Johnson Group Holdings GmbH, Johnson & Johnson Health Care Systems Inc., Johnson & Johnson Hellas Commercial and Industrial S.A., Johnson & Johnson Holding GmbH, Johnson & Johnson Inc., Johnson & Johnson Industrial Ltda., Johnson & Johnson Innovation - JJDC, Johnson & Johnson Innovation Limited, Johnson & Johnson International, Johnson & Johnson International Financial Services Company, Johnson & Johnson Japan Inc., Johnson & Johnson K.K., Johnson & Johnson Korea, Johnson & Johnson Korea Selling & Distribution Limited Liability Company, Johnson & Johnson LLC, Johnson & Johnson Limitada, Johnson & Johnson Limited, Johnson & Johnson Luxembourg Finance Company Sarl, Johnson & Johnson Management Limited, Johnson & Johnson Medical, Johnson & Johnson Medical (China) Ltd., Johnson & Johnson Medical (Shanghai) Ltd., Johnson & Johnson Medical (Suzhou) Ltd., Johnson & Johnson Medical B.V., Johnson & Johnson Medical GmbH, Johnson & Johnson Medical Korea Limited, Johnson & Johnson Medical Limited, Johnson & Johnson Medical Mexico, Johnson & Johnson Medical NV, Johnson & Johnson Medical Products GmbH, Johnson & Johnson Medical Pty Ltd, Johnson & Johnson Medical S.A., Johnson & Johnson Medical S.p.A., Johnson & Johnson Medical Taiwan Ltd., Johnson & Johnson Medikal Sanayi ve Ticaret Limited Sirketi, Johnson & Johnson Middle East FZ-LLC, Johnson & Johnson Nordic AB, Johnson & Johnson Pacific Pty. Limited, Johnson & Johnson Panama S.A., Johnson & Johnson Poland Sp. z o.o., Johnson & Johnson Private Limited, Johnson & Johnson Pte. Ltd., Johnson & Johnson Pty. Limited, Johnson & Johnson Romania S.R.L., Johnson & Johnson S.A., Johnson & Johnson S.A. de C.V., Johnson & Johnson S.p.A., Johnson & Johnson SDN. BHD., Johnson & Johnson Sante Beaute France, Johnson & Johnson Services, Johnson & Johnson Sihhi Malzeme Sanayi Ve Ticaret Limited Sirketi, Johnson & Johnson Swiss Finance Company Limited, Johnson & Johnson Taiwan Ltd., Johnson & Johnson Urban Renewal Associates, Johnson & Johnson Vision Care, Johnson & Johnson Vision Care (Ireland), Johnson & Johnson Vision Care (Shanghai) Ltd., Johnson & Johnson de Argentina S.A.C. e. I., Johnson & Johnson de Chile S.A., Johnson & Johnson de Colombia S.A., Johnson & Johnson de Mexico, Johnson & Johnson del Ecuador S.A., Johnson & Johnson del Peru S.A., Johnson & Johnson do Brasil Industria E Comercio de Produtos Para Saude Ltda., Johnson & Johnson for Export & Import LLC, Johnson & Johnson s.r.o., Johnson & Johnson s.r.o. (Slovakia), Latam International Investment Company, Latam Properties Holdings, LifeScan, LifeScan Products, LifeScan Scotland Limited, Lifescan (France), McNeil AB, McNeil Consumer Pharmaceuticals Co., McNeil Healthcare (UK) Limited, McNeil Healthcare LLC, McNeil Nutritionals, McNeil Products Limited, McNeil Sweden AB, Medical Devices & Diagnostics Global Services, Medos International Sarl, Medos Sarl, Mentor B.V., Mentor Holding PP, Mentor Medical Systems B.V., Mentor Texas L.P., Mentor Worldwide LLC, Micrus Endovascular LLC, Middlesex Assurance Company Limited, Momenta Pharmaceuticals, NeoStrata Company Inc., NeuWave Medical, Novira Therapeutics, OBTECH Medical Sarl, OMJ Ireland, OMJ PR Holdings, Omrix Biopharmaceuticals Ltd., Ortho Biologics LLC, Ortho Biotech Holding LLC, Orthotaxy, PMC Holdings G.K., PT. Johnson & Johnson Indonesia, Patriot Pharmaceuticals, Penta Pty. Limited, Pulsar Vascular, Rutan Realty LLC, SYNTHES Medical Immobilien GmbH, Shanghai Johnson & Johnson Pharmaceuticals, Spectrum Vision Limited Liability Company, SterilMed, Synthes, Synthes GmbH, Synthes Holding AG, Synthes Lux Finance S.àr.l., Synthes Luxembourg, Synthes Produktions GmbH, Synthes USA, Synthes USA Products, TARIS Biomedical, The Anspach Effort, Turnbuckle Investment Company, Vania Expansion, Verb Surgical, Vogue International, XO1, Xian-Janssen Pharmaceutical Ltd., and Zarbee's Naturals.

When was Johnson & Johnson founded?

Johnson & Johnson was founded in 1886.

What is Johnson & Johnson's official website?

The official website for Johnson & Johnson is www.jnj.com.

Where are Johnson & Johnson's headquarters?

Johnson & Johnson is headquartered at ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933.

How can I contact Johnson & Johnson?

Johnson & Johnson's mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company can be reached via phone at (732) 524-0400.


This page was last updated on 9/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.